Search the Warning-Letter Index Before You Take an Offer

What Does the Google Clause Actually Disqualify, Word for Word?

Google's clause disqualifies, in its own words, "Products that have been subject to any government or regulatory action or warning," a line inside the wider Healthcare and medicines policy. It doesn't say products currently making illegal claims. It says any regulatory action or warning, on the product, full stop.

The clause names the product, not the advertiser, and not the ad.

That distinction is why a warning letter against a competitor's near-identical formulation can disqualify the SKU you're about to build a funnel around, even when your own creative has never been touched. The letter attaches to the product's marketing record: website claims, social posts, marketplace listings, customer testimonials. All of it counts as evidence under "any government or regulatory action," not narrowly a strike against Google's own review system.

Why Does Fixing the Landing Page Not Restore the Product's Eligibility?

Fixing the landing page doesn't restore eligibility, because the disqualifier attaches to the product's regulatory record, not to the page a reviewer happened to read. Google's own Abusing the ad network policy defines evasive ad content as "manipulation of ad components such as text, image, videos, domain or subdomains in an attempt to bypass detection." Softening the copy after an FDA letter reads less like remediation and more like the exact pattern that definition names.

Most media buyers treat a rejected ad as a creative problem. For a product carrying a warning letter, it isn't: the SKU is the liability, and no amount of rewriting moves it back across the line.

If a letter has already landed on the specific product you're running, what happens to the account next is its own question, one we cover in what happens after an FDA warning letter hits your peptide or GLP-1 offer.

We could not verify how Google links a disqualified product across an advertiser's other accounts once one gets flagged. Google's policy warns, in the plural, that all of an advertiser's Google Ads accounts will be suspended for circumventing systems, but it doesn't publish the signals it uses to connect them: shared payment profile, shared domain, shared creative. Settling this would need Google to disclose its account-linkage criteria, which as of this writing it hasn't.

How Do You Query FDA's Warning-Letter Index for a Specific Brand or Claim?

You query it directly at FDA's warning-letter database, searching by company name or by the exact claim language you're planning to run, not by disease category. FDA indexes document text, not diagnoses, so "reduce nerve pain" or "restore hearing" returns different results than the underlying condition name would. We ran that search for four verticals while preparing this page: "neuropathy" returns 26 matched letters, "nerve pain" 42, "macular degeneration" 17, "cataracts" 19, "hearing loss" exactly 1, and "deafness" zero.

The one hearing-loss match is worth reading before you trust it as a signal. It's a false positive: a warning letter to Prime Vitality dba Prime Peptides, dated December 10, 2024, where the matched text is a customer-review quote thanking the company, unrelated to any auditory claim, product mechanism or medical condition.

In a 2026 letter to peptide seller PureRawz, FDA quoted its own conclusion back into the record: "evidence obtained from your websites establish that your products are intended to be drugs for human use." That sentence structure, drawn straight from the seller's own marketing language, is exactly what a search on your planned headline claim will surface if a competitor has already been cited for wording close to yours.

Marketplace listings count as evidence too. FDA's letter to Live Good Inc. cited the company's Facebook, Instagram and Amazon storefront pages as proof of an unapproved drug, noting the warning letter that the FTC had reviewed the same websites the month before.

Which of These Niches Carries the Highest Density of Existing Letters?

Vision and neuropathy carry far more matched letters than hearing does, and the gap is wide enough to change how you plan a campaign. The counts below come from FDA's own warning-letter index, searched by term, not from a market-research vendor.

Read the zero and the one carefully.

Neither number is a market-size estimate, and we didn't try to make one out of it. That figure needs CDC or NIH prevalence data we didn't have in hand for this page, so treat any prevalence number circulating on a vendor site as unsourced until you check the primary source yourself. What the index counts do tell you is where FDA has already been looking, which under Google's disqualifier matters more than where the actual health risk sits: a product already caught in that search is disqualified before you write a single headline.

What Do 26 Neuropathy and 42 Nerve Pain Letters Mean for Competitive Research?

They mean the raw count overstates supplement-specific risk unless you filter it, because most matches come from pharmacies, devices and biologics rather than food or supplement companies. Of the 26 neuropathy matches, 7 originate from food or supplement warning letters; of the 42 nerve-pain matches, 19 do.

That filtered number is still your competitive-research floor, not your ceiling, and it pairs naturally with a second question worth asking before you commit budget: how many affiliates are already running the identical offer. A crowded offer with a thin warning-letter record carries a different risk profile than an exclusive one sitting on a thick record.

Under Google's clause, the filtered count still matters more than the raw one, because the two categories carry different weight against the same disqualifier. A pharmacy letter about a compounded drug doesn't touch your capsule-form supplement's eligibility at all. A food-and-supplement letter naming a claim close to your planned headline does, and that's exactly why the search discipline described above pays for itself before the first dollar of media spend goes out the door.

Why Does a Thin Letter Record in Hearing Not Mean a Safer Product?

A thin record in hearing doesn't mean a safer product. It means FDA hasn't gotten around to this niche the way it has vision and neuropathy, and the agency's own reasoning points the other way. FDA's rule on structure/function claims — about normal function, not disease — blesses presbyopia, an aging-related focusing problem, for exactly this kind of claim. But "hearing" appears only twice in the entire final rule and never on the permitted list, and "deafness" appears zero times.

Silence in a rulebook is not the same as permission.

Apply FDA's own two-part disease test and hearing loss lands on the wrong side of it. The agency treats an aging-associated condition as a disease claim once it's uncommon or can cause significant or permanent harm, and sensorineural hearing loss is characteristically permanent, closer to the glaucoma and macular degeneration examples FDA names as remaining diseases than to presbyopia, which is common and correctable. The honest label for hearing's enforcement gap is unresolved, not safe.

What Belongs in an Offer Due-Diligence Checklist Before an Account Is Built?

A due-diligence checklist for these niches starts with the warning-letter search and works outward from there, because a disqualified product makes every other check moot. Run the brand name and your planned claim through FDA's index before you estimate margin, before you check saturation, before anything else.

Run the search first because it's the only check that can end the exercise before you've spent anything at all: if the brand name or its core claim already shows up in FDA's index, or the product sits inside a niche FDA is actively sweeping, vision has letters dated into 2026 and neuropathy has 2026-dated letters too, the Google eligibility question is effectively answered before your ad even has a headline. Only after clearing that hurdle does it make sense to spend time estimating what refund rate the offer is likely running, because refund exposure and platform disqualification are two separate risks draining the same budget on different timelines: refunds bleed slowly through a rising chargeback ratio, while a warning letter kills the account outright and immediately.

On April 13, 2023 the FTC sent Notices of Penalty Offenses to roughly 670 companies in this exact product category, stating plainly it "will not hesitate to use its authority to target violators with large civil penalties." Worth remembering: the FTC's substantiation bar runs independently of whatever claim category FDA assigns the product, so clearing one agency's test proves nothing about the other's.

• Search FDA's warning-letter index by brand name and by your planned headline claim, not just the medical term.
• Check whether the exact product or a near-identical formulation already carries a government action anywhere, since Google's clause reaches any such action, not only its own review process.
• Confirm the offer is still actually paying out before you build creative around it — a listing page is not proof of a live offer, which is its own check covered in [verifying a listed offer is a live offer](/niches/a-listed-offer-is-not-a-live-offer-how-to-verify-before-you-spend).
• Count how many other affiliates are already running the same angle, since a crowded offer changes both your margin and your exposure if the account gets flagged.
• Treat a thin FDA letter record, like hearing's, as unresolved rather than as a green light.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Parasite Copy Has No Compliant Rewrite, The Hangover Angle Is a Disease Claim to FDA, What Counts as 'Substantial Weight Loss' to the FTC, "Hepata-" Anything: The Name FDA Flagged in 2000, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.